You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options

    SBC: Golden Helix, Inc.            Topic: 172

    Abstract Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has undergone rapid advancements. This has occurred alongside a decrease in the cost of genotyping technology, making implementation of pharmacogenomics into clinical practice increasingly feasible. Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.

    SBC: DERMAXON LLC            Topic: NIAMS

    Project Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (atRA) in the epidermis, as an oral treatment for severe recalcitrant acne. This approach will provide an improved acne therapeutic without the adverse effects associated with currently marketed retinoid ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Booth™ by Opio™: Developing technology to expand the reach of opioid treatment programs into rural and underserved areas.

    SBC: Opio Connect, Inc.            Topic: NIDA

    The goal of this project is to develop a treatment booth with technology that allows opioid treatment programs to remotely dispense, either methadone or buprenorphine, under medical observation through telemedicine to a patient in a treatment booth. We believe that robotic automation is the ideal application to perform the same mechanical functions of the nurse at the dosing window. Specifically, ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Constitutive oxalate-biodegrading Bacillus subtilis for kidney stones

    SBC: UNLOCKED LABS INC.            Topic: 400

    Project Summary / AbstractKidney stones (nephrolithiasis) are an extremely painful and debilitating condition. About 12% of people will experience kidney stones in their lifetime, and about 70% of those will have recurrences. The economic burden of kidney stones is estimated to exceed $5 billion per year in the USA alone. Each year, over 3 million workdays are lost in the USA due to kidney stones. ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. PCR-based miRNA assessment of neonatal opioid withdrawal syndrome (NOWS) severity

    SBC: FYR Diagnostics, LLC            Topic: NIDA

    Abstract Opioid use disorder (OUD) has become a national crisis, affecting over 2 million Americans. The number of pregnant women with OUD in the U.S. increased almost 5-fold in the past decade, leading to a similar surge in infants born with neonatal opioid withdrawal syndrome (NOWS), from 1.5 to 8 per 1,000 hospital births (32,000 cases total) between 2004 and 2014. Associated hospital costs hav ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Insect cell lines for glycoprotein structural biology and mannose-dependent protein drugs

    SBC: Glycobac, LLC            Topic: 300

    Project Summary / AbstractThe objective of the proposed research is to create and validate new insect cell lines that can be used to produce glycoproteins (proteins with attached sugars to their surface) specifically for structural biology research. We will engineer insect cell lines so they produce sugar structures that can be removed under non-denaturing conditions, thereby retaining the three-d ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Discovery of NaV1.7 Inhibitors for the Treatment of Pain

    SBC: SITEONE THERAPEUTICS, INC.            Topic: 105

    PROJECT SUMMARY The objective of our program is to develop a safe and effective nonopioid analgesic for the treatment of neuropathic pain, such as pain associated with chemotherapy-induced peripheral neuropathy, that targets an isoform of the voltage-gated sodium ion channel, NaV1.7. Voltage-gated sodium channels are involved in the transmission of nociceptive signals from their site of origin in ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Acoustic Enhanced Cell Culture

    SBC: RESODYN CORPORATION            Topic: 400

    This Small Business Innovation Research Phase I project will develop a prototype and then evaluate a novel device that utilizes low frequency sound energy to enhance cell culture productivityThe acoustic micromixing generated by the proposed device is compatible with cells and possesses the capability to substantially enhance the culture efficiency of cells cultured in typical culture vesselsThis ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough

    SBC: SITEONE THERAPEUTICS, INC.            Topic: NHLBI

    PROJECT SUMMARYThe objective of our program is to develop a safe and effective therapeutic for chronic coughChronic coughor cough that persists for more than eight weeksis a condition that is often associated with diseases such as chronic obstructive pulmonary disorderCOPDasthmaidiopathic pulmonary fibrosisbronchiectasis or gastroesophageal reflux diseaseGERDIn other casesthe etiology is unknownCh ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Topical selective T-type blockers for the treatment of pruritus

    SBC: DERMAXON LLC            Topic: NIAMS

    Project SummaryAbstractPruritusalso called itchis the most frequent dermatological symptom in the US with up toof Americans being affectedPruritic stimuli are detected by a subset of nociceptive neuronspruriceptorswhich fire action potential in response to peripheral activation by THor THmolecules induced by chronic inflammatory skin diseases such as ichthyosisprurigo nodularisand hidradenitis sup ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government